Skip to main content

Table 1 Patient characteristics and distribution of SLC39A6 rs1050631 genotypes

From: Involvement of SLC39A6 in gastric adenocarcinoma and correlation of the SLC39A6 polymorphism rs1050631 with clinical outcomes after resection

Variables

Patients

N (%)

SLC39A6 rs1050631 genotype (N)

P*

Pdominant a

Padditive b

TT(%)

CT(%)

CC(%)

Total

512

20 (3.9)

139 (27.1)

353 (69.0)

   

Age

0.26

0.25

0.14

  < 60

235 (45.9)

6 (1.2)

61 (11.9)

168 (32.8)

   

  ≥ 60

277 (54.1)

14 (2.7)

78 (15.2)

185 (36.1)

   

Gender

0.38

0.18

0.25

 Male

383 (74.8)

15 (2.9)

110 (21.5)

258 (50.4)

   

 Female

129 (25.2)

5 (1.0)

29 (5.7)

95 (18.5)

   

Grade of differentiation

0.85

0.93

0.86

 Well differentiated

21 (4.1)

1 (0.2)

6 (1.2)

14 (2.7)

   

 Moderately differentiated

263 (51.4)

9 (1.8)

75 (14.6)

179 (35.0)

   

 Poorly differentiated

228 (44.5)

10 (2.0)

58 (11.3)

160 (31.2)

   

Gross findings

0.79

0.96

0.81

 Apophysis

35 (6.8)

2 (0.4)

9 (1.8)

24 (4.7)

   

 Invasion

477 (93.2)

18 (3.5)

130 (25.4)

329 (64.3)

   

Lauren classification

0.65

0.45

0.22

 Intestinal type

420 (82.1)

18 (3.5)

119 (23.2)

283 (55.3)

   

 Diffuse type

81 (15.8)

2 (0.4)

18 (3.5)

61((11.9))

   

 Uncertain type

11 (2.1)

0 (0)

2 (0.4)

9 (1.8)

   

Tumor location

0.32

0.38

0.42

 Upper third

179 (35.0)

4 (0.8)

52 (10.2)

123 (24.0)

   

 Middle third

78 (15.2)

4 (0.8)

16 (3.1)

58 (11.3)

   

 Lower third

252 (49.2)

12 (2.3)

69 (13.5)

171 (33.4)

   

 Total

3 (0.6)

0 (0)

2 (0.4)

1 (0.2)

   

Tumor size

0.99

0.88

0.92

  ≥ 5 cm

210 (41.0)

8 (1.6)

58 (11.3)

144 (28.1)

   

  < 5 cm

302 (59.0)

12 (2.3)

81 (15.8)

209 (40.8)

   

Survival

0.002

< 0.001

< 0.001

 Alive

182 (35.5)

4 (0.4)

35 (6.8)

143 (27.9)

   

 Dead

330 (64.5)

16 (3.1)

104 (20.3)

210 (41.0)

   

Recurrence

0.004

< 0.001

< 0.001

 Yes

334 (65.2)

16 (3.1)

104 (20.3)

214 (41.8)

   

 No

178 (34.8)

4 (0.8)

35 (6.8)

139 (27.1)

   

Distant metastasis

0.43

0.87

0.81

 Yes

63 (12.3)

4 (0.8)

15 (2.9)

44 (8.6)

   

 No

449 (87.7)

16 (3.1)

124 (24.2)

309 (60.4)

   

Lymph node metastasis

0.12

0.21

0.08

 Yes

398 (77.7)

19 (3.7)

110 (21.5)

269 (52.5)

   

 No

114 (22.3)

1 (0.2)

29 (5.7)

84 (16.4)

   

Chemotherapy

 Yes

329 (64.3)

13 (2.5)

93 (18.2)

223 (43.6)

0.61

0.78

0.69

 No

183 (35.7)

7 (1.4)

46 (9.0)

130 (25.4)

   
  1. * The χ2 test was used to calculate p values. Fisher’s exact test was used in the analysis of contingency tables when sample size was smaller than 5
  2. a Logistic regression analysis for the dominant model (TT + CT vs CC) was used to calculate the p value
  3. b Logistic regression analysis for the log-additive model was used to calculate the p value by comparing the effect of each additional variant allele